Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Impel Pharmaceuticals Inc. IMPL
$1.56
-$0.49 (-31.58%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
61562283.00000000
-
week52high
10.75
-
week52low
0.93
-
Revenue
12652000
-
P/E TTM
0
-
Beta
-0.32961000
-
EPS
-5.33000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 ноя 2021 г. в 19:30
Описание компании
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| JonesTrading | Buy | 25 авг 2022 г. | |
| Wedbush | Outperform | 18 мая 2021 г. | |
| Guggenheim | Buy | 18 мая 2021 г. | |
| Wedbush | Neutral | Outperform | 15 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Leaman John Harold | D | 0 | 10571 | 31 дек 2022 г. |
| Leaman John Harold | D | 6944 | 3627 | 31 дек 2022 г. |
| Leaman John Harold | A | 10571 | 10571 | 31 дек 2022 г. |
| SHAH MAHENDRA | A | 12789 | 12789 | 16 июн 2022 г. |
| Wilfong Diane E. | A | 12789 | 12789 | 16 июн 2022 г. |
| Allison David D. | A | 12789 | 12789 | 16 июн 2022 г. |
| PARKER H STEWART | A | 12789 | 12789 | 16 июн 2022 г. |
| NELSON TIMOTHY S | A | 12789 | 12789 | 16 июн 2022 г. |
| SHREWSBURY STEPHEN B | D | 0 | 24606 | 29 мар 2022 г. |
| SHREWSBURY STEPHEN B | A | 97990 | 24606 | 29 мар 2022 г. |
Новостная лента
Impel Pharmaceuticals Inc. (IMPL) Q3 2022 Earnings Call Transcript
Seeking Alpha
14 ноя 2022 г. в 13:24
Impel Pharmaceuticals Inc. (NASDAQ:IMPL ) Q3 2022 Results Conference Call November 14, 2022 8:30 AM ET Company Participants John Leaman - Chief Financial & Business Officer Adrian Adams - Chairman & CEO Leonard Paolillo - Chief Commercial Officer Conference Call Participants Ken Cacciatore - Cowen Operator Good morning, ladies and gentlemen, and welcome to Impel Pharmaceuticals Third Quarter 2022 Earnings and Business Update Conference Call. At this time, all participants are in a listen-only mode.
Impel Pharmaceuticals, Inc. (IMPL) CEO Adrian Adams on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
15 авг 2022 г. в 10:33
Impel Pharmaceuticals Inc. (NASDAQ:IMPL ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants John Leaman - Chief Financial & Business Officer Adrian Adams - Chairman & CEO Leonard S. Paolillo - Chief Commercial Officer Conference Call Participants Ken Cacciatore - Cowen Laura Chico - Wedbush Eddie Hickman - Guggenheim Securities Operator Good morning, ladies and gentlemen and welcome to Impel Pharmaceuticals' Second Quarter 2022 Earnings and Business Update Conference Call.
Impel Pharmaceuticals Inc. (IMPL) Reports Q2 Loss, Tops Revenue Estimates
Zacks Investment Research
15 авг 2022 г. в 10:32
Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of 3.54% and 3.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Impel Pharmaceuticals: Under The Radar Despite Upside Potential
Seeking Alpha
28 июн 2022 г. в 02:00
Impel Pharmaceuticals has slipped under the radar since its IPO back in April of last year. The company has made significant progress with its launch of Trudhesa. Impel continues to see Trudhesa prescription momentum increasing and is confident that it will see growth in both new and refill prescriptions.
Impel Pharmaceuticals to Present Trudhesa® Data at the 64th Annual Meeting of the American Headache Society
GlobeNewsWire
09 июн 2022 г. в 08:00
Oral Presentation Showcases Early Ability to Predict Responders to Trudhesa